|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3,965.35 INR | -0.24% |
|
-0.95% | +3.26% |
| Capitalization | 1,345B 14.78B 12.6B 11.67B 10.98B 20.43B 21.92B 135B 53.23B 640B 55.43B 54.29B 2,334B | P/E ratio 2026 * |
54.6x | P/E ratio 2027 * | 44.9x |
|---|---|---|---|---|---|
| Enterprise value | 1,362B 14.96B 12.75B 11.81B 11.11B 20.68B 22.18B 136B 53.87B 647B 56.1B 54.95B 2,363B | EV / Sales 2026 * |
10.4x | EV / Sales 2027 * | 9.16x |
| Free-Float |
30.26% | Yield 2026 * |
0.74% | Yield 2027 * | 0.86% |
Last Transcript: Torrent Pharmaceuticals Limited
| 1 day | -0.20% | ||
| 1 week | -0.95% | ||
| Current month | +3.26% | ||
| 1 month | +4.00% | ||
| 3 months | +10.50% | ||
| 6 months | +12.56% | ||
| Current year | +3.26% |
| 1 week | 3,936 |  | 4,124.95 |
| 1 month | 3,748.4 | | 4,124.95 |
| Current year | 3,829.25 | | 4,124.95 |
| 1 year | 2,891.45 | | 4,124.95 |
| 3 years | 1,446.15 | | 4,124.95 |
| 5 years | 1,155.65 | | 4,124.95 |
| 10 years | 571.75 | | 4,124.95 |
| Manager | Title | Age | Since |
|---|---|---|---|
Aman Samir Mehta
CEO | Chief Executive Officer | 34 | 31/07/2025 |
Sudhir Menon
DFI | Director of Finance/CFO | - | 31/08/2018 |
| Compliance Officer | - | 31/07/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 62 | 29/07/2014 | |
| Director/Board Member | 46 | 07/02/2018 | |
Nayantara Bali
BRD | Director/Board Member | 59 | 06/03/2019 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.24% | -0.95% | +25.63% | +148.50% | 14.78B | |
| +0.28% | -3.33% | +43.48% | +200.89% | 932B | |
| -0.21% | +2.13% | +48.41% | +29.32% | 526B | |
| -0.14% | -3.04% | +24.76% | +43.08% | 378B | |
| -0.23% | +1.50% | +29.64% | +17.57% | 374B | |
| -2.66% | -3.48% | +25.25% | +20.71% | 282B | |
| -1.12% | +0.55% | +28.05% | +35.25% | 278B | |
| +0.57% | +1.10% | +11.77% | -0.45% | 272B | |
| +3.17% | +1.62% | -29.35% | -19.36% | 272B | |
| +0.18% | +2.07% | +21.64% | +25.74% | 178B | |
| Average | -0.20% | +0.10% | +22.93% | +50.13% | 350.66B | |
| Weighted average by Cap. | +0.03% | -0.40% | +28.75% | +69.19% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 130B 1.43B 1.22B 1.13B 1.06B 1.98B 2.13B 13.07B 5.16B 62.03B 5.38B 5.27B 226B | 147B 1.62B 1.38B 1.28B 1.2B 2.24B 2.4B 14.74B 5.82B 69.97B 6.06B 5.94B 255B |
| Net income | 24.35B 268M 228M 211M 199M 370M 397M 2.44B 964M 11.58B 1B 983M 42.26B | 30.2B 332M 283M 262M 246M 459M 492M 3.02B 1.19B 14.36B 1.24B 1.22B 52.4B |
| Net Debt | 16.24B 178M 152M 141M 133M 247M 265M 1.63B 643M 7.72B 669M 656M 28.19B | 2.96B 32.53M 27.72M 25.69M 24.16M 44.97M 48.24M 297M 117M 1.41B 122M 119M 5.14B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 21/01/26 | 3,965.35 ₹ | -0.24% | 1,022 |
| 20/01/26 | 3,974.90 ₹ | -2.83% | 5,355 |
| 19/01/26 | 4,090.80 ₹ | +1.79% | 6,970 |
| 16/01/26 | 4,018.75 ₹ | +0.35% | 2,748 |
| 14/01/26 | 4,004.85 ₹ | +1.66% | 2,225 |
Delayed Quote Bombay S.E., January 21, 2026 at 06:16 am
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- TORNTPHARM Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition